

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b) (Amendment No.)¹

Aldeyra Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

01438T106

(CUSIP Number)

December 31, 2014

Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

[] Rule 13d-1(b)

[] Rule 13d-1(c)

[X] Rule 13d-1(d)

¹The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

1)	Name of Reporting Person L.R.S. Identification		Domain Partners VI, L.P.			
	No. of Above Person					
	(Entities Only)					
	(Voluntary)					
2)	Check the Appropriate Box		(a) [X]			
	if a Member of a Group		(b) []			
3)	SEC Use Only					
4)	Citizenship or Place of Organization		Delaware			
		5)	Sole Voting	1,973,389 shares of Common		
Number of			Power	Stock *		
Shares		6)	Shared Voting			
Beneficially		•	Power	-0-		
Owned by		7)	Sole Dispositive	1,973,389 shares of Common		
Each		,	Power	Stock *		
Reporting Person		8)	Shared Dispositive Power			
With		,	1	-0-		
9)	Aggregate Amount Beneficially					
	Owned by Each Reporting Person 1,973,389 shares of Common Stock *					
10)	Check if the Aggregate Amount in					
	Row (9) Excludes Certain Shares					
11)	Percent of Class Represented by					
	Amount in Row (9)		35.5% **			
12)	Type of Reporting Person		PN			

^{*} As of December 31, 2014
** Based on 5,565,415 shares of Common Stock outstanding as of December 31, 2014

1)	Name of Reporting Person I.R.S. Identification		DP VI Associates, L.P.	
	No. of Above Person			
	(Entities Only) (Voluntary)			
3)	Check the Appropriate Box		(a) [X]	
2)	if a Member of a Group		(a) [A] (b) []	
2)			(0)[]	
3)	SEC Use Only		- 1	
4)	Citizenship or Place of Organization		Delaware	
		5)	Sole Voting	9,208 shares of Common Stock
Number of			Power	*
Shares		6)	Shared Voting	
Beneficially		- /	Power	-0-
Owned by		7)	Sole Dispositive	9,208 shares of Common Stock
Each		<i>')</i>	Power	*
Reporting		0)		
Person		8)	Shared Dispositive Power	-0-
With				-0-
9)	Aggregate Amount Beneficially			
	Owned by Each Reporting Person		9,208 shares of Common Stock *	
10)	Check if the Aggregate Amount in			
	Row (9) Excludes Certain Shares			
11)	Percent of Class Represented by			
	Amount in Row (9)		0.2% **	
12)	Type of Reporting Person		PN	

^{*} As of December 31, 2014

^{**} Based on 5,565,415 shares of Common Stock outstanding as of December 31, 2014

Schedule 13G

Item 1(a) – Name of Issuer: Aldeyra Therapeutics, Inc.

Item 1(b) – Address of Issuer's Principal Executive Offices:

15 New England Executive Park Burlington, MA 01803

Item 2(a) – Name of Person Filing:

This statement is being filed by Domain Partners VI, L.P., a Delaware limited partnership ("Domain VI"), and DP VI Associates, L.P., a Delaware limited partnership ("DP VI A") (together, the "Reporting Persons").

Item 2(b) - Address of Principal Business Office:

One Palmer Square Princeton, NJ 08542

Item 2(c) – Place of Organization:

Domain VI: Delaware DP VI A: Delaware

Item 2(d) - Title of Class of Securities:

Common Stock, \$0.001 par value

Item 2(e) - CUSIP Number: 01438T106

Item 3 - Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):

Not applicable.

Item 4 – Ownership.

(a) through (c):

The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference. In addition, as of December 31, 2014 Domain Associates, L.L.C., an affiliate and the investment manager of the Reporting Persons, directly beneficially owned 10,358 shares of Common Stock, or approximately 0.2% of the Common Stock outstanding.

Item 10 – Certification:

Not applicable.

CUSIP No. 01438T106 Page 6 of 8 Pages

Signature:

After reasonable inquiry and to the best of their knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2015

DOMAIN PARTNERS VI, L.P.

By: One Palmer Square Associates VI, L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member

DP VI ASSOCIATES, L.P.

By: One Palmer Square Associates VI, L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 2, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 3, 2015

DOMAIN PARTNERS VI, L.P.

By: One Palmer Square Associates VI, L.L.C., General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member
DP VI ASSOCIATES, L.P.

By: One Palmer Square Associates VI, L.L.C.,

General Partner

By: /s/ Kathleen K. Schoemaker

Managing Member

Identification and Classification of Members of the Group

Domain Partners VI, L.P. and DP VI Associates, L.P. are filing this statement on Schedule 13G as a group.

Domain Partners VI, L.P. is a Delaware limited partnership. Its sole general partner is One Palmer Square Associates VI, L.L.C., a Delaware limited liability company.

DP VI Associates, L.P. is a Delaware limited partnership. Its sole general partner is One Palmer Square Associates VI, L.L.C., a Delaware limited liability company.